Tempus expands multi-year Merck collaboration giving Merck access to de-identified multimodal data and Lens platform

Tempus holds the de-identified multimodal oncology substrate and operates the Lens Platform with Workspaces that Merck uses; enrichment work (dataset curation, Lens tooling) is done on Tempus' side, while Merck runs biomarker queries inside that environment for its own programs.

The substrate's value to Merck is that linked clinical-molecular-imaging records at Tempus' scale support the call Merck is actually paying to make - which oncology biomarker hypotheses to advance into trials, and potentially expansion into other therapeutic areas as the release states.

What crossed is de-identified multimodal data access and use of the Lens Platform with Workspaces for the term of the collaboration; what did not cross is ownership of the underlying patient-level substrate or the Lens tooling itself. Per the announcement no financial terms were disclosed, so exclusivity and field-of-use carve-outs are not public.

Not determinable: with no disclosed deal value, no stated duration beyond 'multi-year', and no scope figures on data volume or therapeutic areas covered, the public facts do not settle whether Tempus priced this against the value Merck will extract.